22nd Century Group, Inc.

22nd Century Group, Inc.

22nd Century Group was founded in 1998 and is headquartered in Mocksville, North Carolina. The company went public in 2005 on the NYSE American under the ticker XXII, transitioning from a small research operation to a vertically integrated plant biotechnology firm. Its core focus spans reduced-nicotine tobacco through proprietary gene-editing techniques and hemp-derived CBD products via its subsidiary, Botanical Genetics, LLC. The company's strategy combines in-house R&D with commercial manufacturing. 22nd Century operates a 12,000-square-foot research facility in North Carolina and a hemp processing plant in Kentucky. Its product lineup includes VLN® cigarettes, the first and only reduced-nicotine tobacco product authorized for marketing by the FDA (per FDA, December 2021), and a range of hemp-derived CBD consumer goods. The firm also holds patents covering methods for controlling nicotine biosynthesis in tobacco plants. As of 2023, 22nd Century Group reported approximately 15 full-time employees. The company maintains no disclosed multi-family office structure, registered investment advisory arm, or philanthropic foundation separate from its corporate operations. Recent public filings indicate ongoing restructuring efforts and operational streamlining (per SEC filings, 2024). A structural differentiator relative to ag-biotech peers is 22nd Century's direct-to-consumer and wholesale CBD distribution channel, alongside FDA-regulated tobacco products — an unusual regulatory and commercial straddle that few publicly traded companies attempt. Its ownership base consists entirely of public shareholders, with no underlying family-office or endowment anchor investor disclosed.